As shown in Figures 7C–G, three doses of an ICV consisting of VSVΔ51 or MG1 conferred significant antitumoral protection against ID8-p53−/− tumors, which was evident even during early tumor growth as shown by Gaussia-luciferase activity (Figure 7F). This evidence concerns the gene TP53 and neoplasm.